Please login to the form below
cell and gene therapies
This page shows the latest cell and gene therapies news and features for those working in and with pharma, biotech and healthcare.
bluebird bio sells second FDA priority review voucher for $95m
bluebird bio received two PRVs upon the FDA approvals of Zynteglo (betibeglogene autotemcel) for the treatment of beta-thalassaemia in adult and paediatric patients requiring regular red blood cell transfusions, and ... commercial launches of our two
Latest news
-
UK government announce £260m to boost healthcare research and manufacturing
An additional £60m will support investments in commercial-scale manufacturing made by companies, including further funding for cell and gene therapies and medical devices. ... This follows on from the success of the earlier Medicines and Diagnostics
-
AstraZeneca officially opens new R&D facility in UK
said. The Discovery Centre will support AstraZeneca’s focus on specialised and precision medicines and foster the discovery and development of next-generation therapeutics, including nucleotide-based, gene-editing and cell ... therapies, said the
-
UK’s NICE to revamp its processes to make access to medicines “fairer”
The health technology assessment body is running a consultation to make its processes “clear, transparent and predictable”. ... enough. “We are disappointed that proposals to appropriately value the long-term benefits of potentially curative
-
Ashfield launches ‘end-to-end’ cell and gene therapy commercialisation network
UDG Healthcare company Ashfield has launched a new network offering an end-to-end approach for the commercialisation of cell and gene therapies. ... Health. “EmerGENE is no different, and with over 1, 200 cell and gene therapy clinical trials currently
-
BioNTech on course to produce three billion doses of Pfizer-partnered COVID-19 vaccine in 2021
Novartis is providing support with a production site in the German city of Marburg, which is fully equipped for the production of recombinant proteins, as well as cell and gene therapies. ... Additional measures and discussions with potential partners to
More from news
Approximately 3 fully matching, plus 57 partially matching documents found.
Latest Intelligence
-
Focusing on ‘treating the patient, not the disease’ can transform the outlook for cardiovascular disease
Recent data on our investigational CV product portfolio underscores our commitment to investing in therapies that slow or prevent CVDs as we strive to make significant developments towards the prevention of ... CVD. For example, we are investigating cell
-
The Age of Diversity, Equality and Inclusion
It also signals fresh potential for existing drugs and new generations of cell and gene therapies to reach more patients. ... shackle the advance of innovative therapies, as well as contributing to poor health and premature deaths.
-
CAR-T cell therapy in oncology
In working with oncology CAR-T therapies, the stakes for an efficient cell and gene therapy (CGT) supply chain are especially high because recipients are often in the later stages of ... Broader applicability to a range of solid tumours. One thing is
-
Who needs to be trusted anyway?
Let’s take this one step further. Cell and gene therapies are a new frontier in medicine that only pharma has the scientific and clinical know-how to bring to market, ... see wholesale change in healthcare (ASGCT, Gene, Cell, &RNA Therapy Landscape
-
EU cross-border healthcare
The clock is ticking to improve access to gene and cell therapies for rare diseases. ... A complex and little-known framework that fails to address the specificities of gene and cell therapies.
More from intelligence
Approximately 1 fully matching, plus 25 partially matching documents found.
Latest appointments
-
Health comms agency emotive hires new cell and gene therapy leader
An expert in cell and gene therapies, Dr Ferrari joins emotive following 20 years in research as well as holding medical affairs and commercial roles in biopharma and diagnostics. ... It is also charged with developing HCP engagement on gene silencing
-
Abeona Therapeutics appoints new additions to board of directors
Stefano Buono and Richard Van Duyne join the biopharma. Abeona Therapeutics, a clinical stage biopharmaceutical company focused on developing cell and gene therapies, has expanded its board of directors through the ... He said: “Abeona’s ambitious
-
Avita Medical appoints CEO
chief scientific officer, global business development and licensing, and chief scientific officer for its cell and gene therapy unit. ... and gene therapies for Novartis subsidiaries Systemix Inc.
-
Paul Blake joins Oxford BioMedica
He will head the clinical development of the company's pipeline of gene and cell therapies. ... therapies will be important to Oxford BioMedica as we continue to develop our broad pipeline of novel gene and cell therapies.”.
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
The fast-paced future of cell and gene therapies
In this report, we interview patients, researchers, and biopharmaceutical leaders to explore the complex landscape for the development of cell and gene therapies and share commercial recommendations from our specialist teams. ... Cell and gene therapies
-
The desire for connected customer experiences unites stakeholders
There are more therapies to choose from and different kinds of treatments such as cell and gene therapies that require entirely different engagement models. ... And patients, while increasingly empowered, still struggle to meaningfully engage in
-
Generating data on long-term outcomes with gene and other advanced therapies
Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’. ... Early experience with existing gene therapies has shown that long-term outcome monitoring can be challenging, but with the right
-
Precision medicine with precision management and precision pricing; ensuring affordability in the cell and gene therapy era
The imminent explosion of cell and gene therapies raises issues of affordability for all health systems, not just for low and middle income countries. ... Potential methods of payment proposed for expensive cell and gene therapies include:.
-
OPEN Health
Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’. ... Precision medicine with precision management and precision pricing; ensuring affordability in the cell and gene therapy era.
More from PMHub
Approximately 0 fully matching, plus 10 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- Europe’s cancer community publishes new report on transforming patient care
- EU outlines measures to mitigate antibiotic shortage across Europe
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Diversifying Healthcare AI with Federated Learning
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- EU to revise pharmaceuticals law amid antibiotic shortages
- European MPs call for urgent action against antimicrobial resistance
- The role of medical communications in building credibility for healthtech
PMHub
Redbow Consulting Group
Redbow Consulting Group is a specialist healthcare management consultancy specialising in business strategy and marketing...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
